
(
  (S
    (NP
      (NP (NN Tissue) (NN factor))
      (PP (IN as)
        (NP (DT a) (JJ proinflammatory) (NN agent))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (NP
        (NP (NN Tissue) (NN factor))
        (PRN (-LRB- -LRB-)
          (NP (NN TF))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (NP
          (NP (DT a) (JJ transmembrane) (NN glycoprotein))
          (CC and)
          (NP
            (NP (DT the) (JJ main) (NN triggering) (NN element))
            (PP (IN of)
              (NP (NN blood) (NN coagulation)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN TF) (NN expression))
        (PP (IN on)
          (NP
            (NP (NNS monocytes))
            (CC and)
            (NP (JJ endothelial) (NNS cells)))))
      (VP
        (VP (VBZ is)
          (VP (VBN induced)
            (PP (IN by)
              (NP
                (NP (NN exposure))
                (PP (TO to)
                  (NP
                    (NP (NN endotoxin))
                    (, ,)
                    (NP (NN tumor) (NN necrosis) (NN factor))
                    (, ,)
                    (CC and)
                    (NP (NN IL-1))))))))
        (CC and)
        (VP (VBZ is)
          (VP (VBN considered)
            (S
              (VP (TO to)
                (VP (VB appear)
                  (PP (IN in)
                    (NP
                      (NP (NN consequence))
                      (PP (IN of)
                        (NP (NN inflammation))))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN In) (NN order)
        (S
          (VP (TO to)
            (VP (VB assess)
              (NP
                (NP (DT the) (JJ proinflammatory) (NN capacity))
                (PP (IN of)
                  (NP (NN TF) (PRP itself))))))))
      (, ,)
      (NP
        (NP (DT the) (JJ recombinant) (JJ extracellular) (NN domain))
        (PP (IN of)
          (NP (NN TF))))
      (VP (VBD was)
        (VP (VBN injected)
          (ADVP (RB intra-articularly))
          (PP (IN into)
            (NP (JJ healthy) (NNS mice))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB characterize)
            (NP
              (NP (DT the) (NN role))
              (PP (IN of)
                (NP (JJ immune) (NNS cells)))
              (PP (IN in)
                (NP (DT the) (JJ TF-induced) (NN arthritis)))))))
      (, ,)
      (NP
        (NP (NNS mice))
        (VP (VBN deprived)
          (PP (IN of)
            (NP
              (NP (NNS lymphocytes))
              (, ,)
              (NP (NNS neutrophils))
              (CC and)
              (NP (NNS monocytes))))))
      (VP (VBD were)
        (VP (VBN used))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Histomorphological) (NN analysis))
        (PP (IN of)
          (NP (DT the) (NNS joints)))
        (PP (IN with)
          (NP
            (NP (NN respect))
            (PP (TO to)
              (NP
                (NP (JJ inflammatory) (NN cell) (NN infiltration))
                (, ,)
                (NP (NN pannus) (NN formation))
                (CC and)
                (NP (NN erosion) (NN formation)))))))
      (VP (VBD revealed)
        (NP
          (NP (NN development))
          (PP (IN of)
            (NP (NN arthritis))))
        (PP (IN in)
          (NP
            (NP (CD 80) (NN %))
            (PP (IN of)
              (NP
                (NP (NNS animals))
                (VP (VBN injected)
                  (PP (IN with)
                    (NP (NN TF))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (JJS most))
          (PP (IN of)
            (NP (DT the) (NNS cases)))))
      (NP (JJ synovial) (NN proliferation))
      (VP (VBD was)
        (VP (VBN accompanied)
          (PP (IN by)
            (NP
              (NP (NN pannus) (NN formation))
              (CC and)
              (NP (NN cartilage) (NN destruction)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Inflammatory) (NN cell) (NN infiltrate))
      (VP (VBD consisted)
        (PP (IN of)
          (NP (JJ CD4-Mac1+) (NNS macrophages)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Depletion))
        (PP (IN of)
          (NP (NNS monocytes))))
      (VP (VBD was) (, ,)
        (ADVP (RB however))
        (, ,) (RB not)
        (S
          (ADVP (RB enough))
          (VP (TO to)
            (VP (VB abolish)
              (NP (NN inflammation)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Indeed))
      (, ,)
      (NP
        (NP (JJ combined) (NN deficiency))
        (PP (IN of)
          (NP
            (NP (NNS monocytes))
            (CC and)
            (NP (NNS lymphocytes)))))
      (VP (VBD was)
        (VP (VBN required)
          (S
            (VP (TO to)
              (VP (VB prevent)
                (NP (NN inflammation))
                (PP (VBG following)
                  (NP
                    (NP (DT the) (NN injection))
                    (PP (IN of)
                      (NP (NN TF)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD observed)
        (SBAR (IN that)
          (S
            (NP (NN TF))
            (VP
              (VP (VBD induced)
                (NP
                  (NP (NN chemokine) (NN production))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN MIP-1α))
                      (CC and)
                      (NP (NN RANTES)))
                    (-RRB- -RRB-))))
              (, ,)
              (CC but)
              (VP (VBD did) (RB not)
                (VP (VB induce)
                  (NP
                    (NP (DT a) (JJ proliferative) (NN response))
                    (CC nor)
                    (NP
                      (NP (NN cytokine) (NN release))
                      (PP (IN by)
                        (NP (NN mouse) (NN spleen) (NNS cells))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN TF))
      (VP (VBZ has)
        (NP
          (NP
            (NP (JJ strong) (JJ inflammatogenic) (NNS properties))
            (VP (VBN mediated)
              (ADVP (RB predominantly))
              (PP (IN by)
                (NP (NNS monocytes)))))
          (CC and)
          (NP
            (NP (PRP$ their) (NN release))
            (PP (IN of)
              (NP (NNS chemokines)))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NN study))
      (VP (VBZ shows)
        (SBAR (IN that)
          (S
            (NP (NN TF))
            (VP (MD can)
              (ADVP (RB simultaneously))
              (VP (VB trigger)
                (NP (DT the) (JJ immune)
                  (CC and)
                  (NN coagulation) (NNS systems))))))))
    (. .)))

(
  (S
    (NP (NN Introduction))))

(
  (S
    (S
      (NP
        (NP (NN Tissue) (NN factor))
        (PRN (-LRB- -LRB-)
          (NP (NN TF))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (NP
          (NP (DT a) (JJ transmembrane) (NN glycoprotein))
          (CC and)
          (NP
            (NP (DT the) (JJ major) (JJ cellular) (NN trigger))
            (PP (IN of)
              (NP (NN blood) (NN coagulation)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Assembly))
        (PP (IN of)
          (NP (DT a) (NN complex)))
        (PP (IN between)
          (NP
            (NP (NN TF))
            (CC and)
            (NP
              (NP (NN factor) (NN VII))
              (PRN (-LRB- -LRB-)
                (NP (NN FVII))
                (-RRB- -RRB-))))))
      (VP (VBZ initiates)
        (NP (NN fibrin) (NN formation))))
    (. .)))

(
  (S
    (S
      (PP (IN Besides)
        (NP
          (NP (PRP$ its) (NN role))
          (PP (IN in)
            (NP (NN blood) (NN coagulation)))))
      (, ,)
      (NP (NN TF))
      (VP (VBZ is)
        (ADVP (RB also))
        (ADJP (JJ important)
          (PP (IN for)
            (NP
              (NP (DT the) (JJ vascular) (NN development))
              (VP
                (VP (VBG regulating)
                  (NP (JJ embryonic) (NN angiogenesis)))
                (CC and)
                (VP (VBG supporting)
                  (NP
                    (NP
                      (ADJP
                        (ADJP (JJ proliferative))
                        (CC and)
                        (ADJP (JJ invasive)))
                      (NNS capacities))
                    (PP (IN of)
                      (NP (NNS cells) (CD -LSB-1-4) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Expression))
          (PP (IN of)
            (NP (NN TF)))
          (PP (IN on)
            (NP (DT the) (NN cell) (NN surface))))
        (CC and)
        (NP
          (NP (PRP$ its) (NN appearance))
          (PP (IN as)
            (NP (DT a) (JJ soluble) (NN molecule)))))
      (VP (VBP are)
        (NP
          (NP (JJ characteristic) (NNS features))
          (PP (IN of)
            (NP
              (ADJP
                (ADJP (JJ acute))
                (CC and)
                (ADJP (JJ chronic)))
              (NN inflammation))))
        (PP (IN in)
          (NP
            (NP (NNS conditions))
            (PP (JJ such) (IN as)
              (NP
                (NP (NN sepsis))
                (, ,)
                (NP (NN atherosclerosis))
                (, ,)
                (NP (NN Crohn) (POS 's) (NN desease))
                (, ,)
                (NP (JJ systemic) (NN lupus) (NN erythematosus))
                (, ,)
                (CC and)
                (NP (NN rejection) (NNS reactions))
                (NP (NN -LSB-5-9))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN role))
        (PP (IN of)
          (NP (NN TF)))
        (PP (IN in)
          (NP (DT the) (JJ inflammatory) (NN process))))
      (VP (VBZ is)
        (NP
          (NP (DT a) (NN matter))
          (PP (IN of)
            (NP (NN discussion))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NN variety))
        (PP (IN of)
          (NP
            (NP (JJ inflammatory) (NNS stimuli))
            (, ,)
            (PP (VBG including)
              (NP
                (NP (NNS mitogens))
                (, ,)
                (NP (JJ bacterial) (NN cell) (NNS products))
                (, ,)
                (NP
                  (NP (NNS components))
                  (PP (IN of)
                    (NP (DT the) (NN complement) (NN system))))
                (CC and)
                (NP (NNS cytokines))))
            (, ,))))
      (VP (VBP are)
        (VP (VBN known)
          (S
            (VP (TO to)
              (VP (VB promote)
                (NP
                  (NP (DT the) (NN expression))
                  (PP (IN of)
                    (NP (NN TF)))
                  (PP (IN on)
                    (NP
                      (NP (DT the) (NN surface))
                      (PP (IN of)
                        (NP
                          (NP (JJ endothelial) (NNS cells))
                          (CC and)
                          (NP (NNS monocytes) (CD -LSB-10) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN T) (NNS cells))
      (VP (VBP regulate)
        (NP (NN TF) (NN expression))))
    (: :)
    (S
      (NP (NN upregulation))
      (VP (VBZ is)
        (VP (VBN achieved)
          (PP (IN by)
            (NP (NN Th1) (NNS cytokines)))
          (, ,)
          (SBAR (IN while)
            (S
              (NP (JJ Th2-derived) (NNS cytokines))
              (VP (VBP are)
                (ADVP (RB mostly))
                (NP (JJ inhibitory) (NN -LSB-11)))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (NN TF))
      (, ,)
      (PP (IN in)
        (NP (NN turn)))
      (, ,)
      (VP (MD may)
        (VP (VB participate)
          (PP (IN in)
            (S
              (NP (JJ cellular) (NNS interactions))
              (VP (VBG promoting)
                (NP
                  (NP (NN leukocyte) (NN adhesion))
                  (CC and)
                  (NP (JJ transendothelial) (NN migration) (CD -LSB-12,13))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ present) (NN study)))
      (NP (PRP we))
      (VP (VBD investigated)
        (NP
          (NP (DT the) (NN capacity))
          (PP (IN of)
            (NP (NN TF)))
          (S
            (VP (TO to)
              (VP (VB induce)
                (NP (NN inflammation))
                (PP (IN by)
                  (S
                    (VP (VBG injecting)
                      (NP
                        (NP (JJ human) (JJ recombinant) (NN TF))
                        (PRN (-LRB- -LRB-)
                          (NP (NN rTF))
                          (-RRB- -RRB-)))
                      (PP (IN into)
                        (NP
                          (NP (NN joint) (NNS cavities))
                          (PP (IN of)
                            (NP (JJ healthy) (NNS mice))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Histomorphological) (NN investigation))
        (PP (IN of)
          (NP (DT the) (VBN injected) (NNS joints))))
      (VP (VBD showed)
        (NP
          (NP
            (NP (DT a) (JJ remarkable) (JJ cellular) (NN infiltration))
            (PP (IN of)
              (NP (NN synovia))))
          (CC and)
          (ADVP (RB occasionally))
          (NP (NN cartilage) (NN destruction)))
        (, ,)
        (S
          (VP (VBG indicating)
            (SBAR (IN that)
              (S
                (NP (NN TF))
                (VP (VBZ possesses)
                  (NP (JJ strong) (JJ proinflammatory) (NNS properties)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Expression))
        (PP (IN of)
          (NP (NN TF)))
        (PP (IN on)
          (NP
            (NP (NNS monocytes))
            (CC and)
            (NP (JJ synovial) (NNS cells)))))
      (VP (MD may)
        (VP (VB be)
          (ADJP (JJ crucial)
            (PP (IN for)
              (S
                (VP (VBG potentiating)
                  (NP
                    (NP (DT the) (JJ initial) (NNS stages))
                    (PP (IN of)
                      (NP
                        (NP (NN inflammation))
                        (PP (IN in)
                          (NP (NNS joints)))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Materials))
      (CC and)
      (NP (NNS methods)))))

(
  (S
    (S
      (NP (NN BALB/c)
        (CC and)
        (NN NMRI) (NNS mice))
      (VP (VBD were)
        (VP (VBN purchased)
          (PP (IN from)
            (NP (NN ALAB)))
          (PRN (-LRB- -LRB-)
            (NP (NNP Stockholm) (, ,) (NNP Sweden))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Severe) (JJ combined) (JJ immunodeficient) (-LRB- -LRB-) (NN SCID) (-RRB- -RRB-) (NNS mice))
        (CC and)
        (NP (PRP$ their) (JJ congenic) (NN strain) (CD CB17)))
      (VP (VBD were)
        (VP (VBN purchased)
          (PP (IN from)
            (NP
              (NP (NNP M&B))
              (PRN (-LRB- -LRB-)
                (NP (NNP Bomholtvej) (, ,) (NNP Denmark))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS mice))
      (VP (VBD were)
        (VP (VBN housed)
          (PP (IN in)
            (NP
              (NP (DT the) (JJ animal) (NN facility))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN Department))
                  (PP (IN of)
                    (NP
                      (NP (NNP Rheumatology) (, ,) (NNP University))
                      (PP (IN of)
                        (NP (NN Göteborg))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Female) (NNS mice))
        (PP (IN 6–8)
          (NP
            (NP (NNS weeks))
            (PP (IN of)
              (NP (NN age))))))
      (VP (VBD were)
        (VP (VBN used)
          (PP (IN in)
            (NP (PDT all) (DT the) (NNS experiments))))))
    (. .)))

(
  (S
    (NP
      (NP (DT This) (NN version))
      (PP (IN of)
        (NP (NN rTF))))
    (VP (VBZ contains)
      (NP
        (NP
          (NP
            (NP
              (NP (DT the) (JJ extracellular) (NN domain))
              (PP (IN of)
                (NP (JJ human) (NN TF))))
            (, ,)
            (NP (NN amino) (NN acid) (NNS residues)))
          (NP (NN 1–219) (CD -LSB-14) (-RRB- -RSB-)))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VBZ retains)
              (NP (DT the) (NN ability)
                (S
                  (VP
                    (VP (TO to)
                      (VP (VB bind)
                        (PP (TO to)
                          (NP
                            (NP (NN FVII))
                            (CC and)
                            (NP (NN FVIIa))))))
                    (CC and)
                    (VP (TO to)
                      (VP (VB enhance)
                        (NP
                          (NP (JJ enzymatic) (NN activity))
                          (PP (IN of)
                            (NP (NN FVIIa))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN rTF) (NN preparation))
      (VP (VBD was)
        (VP
          (VP (VBN dissolved)
            (PP (IN in)
              (NP
                (NP (NN Hepes) (JJ buffered) (NN saline))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NNP Hepes))
                    (ADJP (CD 30) (NN mM)))
                  (, ,)
                  (NP
                    (NP
                      (NP (NN NaCl))
                      (ADJP (CD 100) (NN mM)))
                    (, ,)
                    (NP
                      (ADJP (CD 0.02) (NN %))
                      (NN Na-azide) (: ;) (CD pH7.5)))
                  (-RRB- -RRB-)))))
          (CC and)
          (VP (VBN kept)
            (PP (IN in)
              (NP
                (NP (NNS aliquots))
                (PP (IN at)
                  (NP
                    (NP (CD -70°C))
                    (PP (IN until)
                      (NP (NN use)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD Two) (NNS preparations))
        (PP (IN of)
          (NP (NN TF))))
      (VP (VBD were)
        (VP (VBN used)
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBD contained)
                (NP
                  (NP (CD 3.7) (NN μg/ml))
                  (CC and)
                  (NP
                    (NP (CD 32) (NN ng/ml))
                    (PP (IN of)
                      (NP
                        (NP (NN lipopolysaccharide))
                        (PRN (-LRB- -LRB-)
                          (NP (NN LPS))
                          (-RRB- -RRB-))))))
                (, ,)
                (ADVP (RB respectively))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (DT No) (JJ significant) (NN difference))
          (PP (IN in)
            (NP
              (NP (DT the) (NNS results))
              (VP (VBN obtained)
                (PP (IN with)
                  (NP (DT these) (CD two) (NNS preparations)))))))
        (VP (VBD was)
          (VP (VBN observed))))
      (CC and)
      (S
        (NP (DT the) (NNS results))
        (VP (VBD were)
          (ADVP (RB thus))
          (ADJP (JJ pooled)))))
    (. .)))

(
  (S
    (S
      (NP (NN NMRI) (NN strain) (NNS mice))
      (VP (VBD were)
        (VP (VBN used)
          (PP (IN in)
            (NP (DT the) (NNS experiments)))
          (SBAR (IN unless)
            (S
              (VP (VBN stated)
                (ADVP (RB otherwise))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Induction))
        (PP (IN of)
          (NP (NN arthritis))))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN by)
            (NP
              (NP (NN injection))
              (PP (IN of)
                (NP
                  (NP (NN rTF))
                  (PP (IN in)
                    (NP
                      (NP (DT a) (NN volume))
                      (PP (IN of)
                        (NP
                          (ADJP (CD 20) (NN μl))
                          (NN intra-articularly)))))))
              (PP (IN into)
                (NP (DT the) (JJ right) (NN knee) (NN joint))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Control) (NNS experiments))
      (VP (VBD were)
        (VP (VBN performed)
          (PP (IN by)
            (S
              (VP (VBG injecting)
                (NP
                  (NP (DT an) (JJ equivalent) (NN amount))
                  (PP (IN of)
                    (NP (NN LPS) (NN preparation)))
                  (PP (IN in)
                    (NP (NN Hepes) (JJ buffered) (NN saline))))
                (PP (IN into)
                  (NP (DT the) (JJ contralateral) (JJ knee) (NN joint)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Neutrophil) (NN depletion))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN by)
            (NP
              (NP (JJ intraperitoneal) (NN injection))
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ monoclonal) (NN antibody) (CD RB6-8C5))
                  (PRN (-LRB- -LRB-)
                    (S
                      (NP (NN hybridoma))
                      (VP (VBD was)
                        (ADVP (RB kindly))
                        (VP (VBN provided)
                          (PP (IN by)
                            (NP
                              (NP (NN Dr) (NN R) (NNP Coffman))
                              (, ,)
                              (NP (NN DNAX) (NN Research) (NN Institute))
                              (, ,)
                              (NP (NNP Palo) (NNP Alto))
                              (, ,)
                              (NP (NN CA) (, ,) (NNP USA)))))))
                    (-RRB- -RRB-))))))
          (PP
            (NP (CD two) (NNS hours))
            (IN before)
            (NP (DT the) (NN rTF) (NN injection))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN described)
              (ADVP (RB previously))
              (S
                (NP (NN -LSB-15))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN IgG) (NN rat) (NN antiovalbumin) (JJ monoclonal) (NN antibody))
        (-LRB- -LRB-)
        (VP
          (ADVP (RB kindly))
          (VBN provided)
          (PP (IN by)
            (NP
              (NP (NN Dr) (NNP E) (NNP Telemo) (, ,) (NNP Department))
              (PP (IN of)
                (NP
                  (NP (JJ Clinical) (NN Immunology) (, ,) (NNP University))
                  (PP (IN of)
                    (NP (NNP Göteborg) (, ,) (NNP Sweden))))))))
        (-RRB- -RRB-))
      (VP (VBD was)
        (VP (VBN injected)
          (PP (IN into)
            (NP (DT the) (JJ control) (NN group))))))
    (. .)))

(
  (S
    (S
      (NP (NN Monocyte) (NN depletion))
      (VP (VBD was)
        (VP (VBN induced)
          (PP (IN by)
            (NP
              (NP (JJ subcutaneous) (NN injection))
              (PP (IN of)
                (NP (NN etoposide)))))
          (PRN (-LRB- -LRB-)
            (NP (NNP Bristol-Myers) (NNP Squibb) (, ,) (NNP Bromma) (, ,) (NNP Sweden))
            (: ;)
            (NP (CD 12.5) (NN mg/kg) (NN body) (NN weight))
            (, ,)
            (NP
              (PP (IN in)
                (NP
                  (NP (DT a) (NN volume))
                  (PP (IN of)
                    (NP
                      (ADJP (CD 100) (NN μl))
                      (NN -LSB-16)))))
              (-RRB- -RSB-))
            (-RRB- -RRB-))
          (PP (IN on)
            (NP
              (NP
                (NP (CD three) (JJ consecutive) (NNS days))
                (PP (IN before)))
              (CC and)
              (NP
                (NP (CD three) (JJ consecutive) (NNS days))
                (PP (IN after)
                  (NP
                    (NP (NN injection))
                    (PP (IN of)
                      (NP (NN rTF)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN impact))
        (PP (IN of)
          (NP (NNS lymphocytes))))
      (VP (VBD was)
        (VP (VBN studied)
          (PP (IN by)
            (S
              (VP (VBG injecting)
                (NP (NN rTF))
                (PP (IN into)
                  (NP
                    (NP (NN SCID) (NNS mice))
                    (VP (VBG lacking)
                      (NP
                        (NP
                          (NP (NN B))
                          (CC and)
                          (NP (NN T))
                          (NP (NNS lymphocytes)))
                        (CC and)
                        (NP
                          (NP (PRP$ their) (JJ congenic) (NN strain))
                          (, ,)
                          (NP (NN CB17)))))))))))))
    (. .)))

(
  (S
    (NP (DT This))
    (VP (VBD was)
      (VP (VBN achieved)
        (PP (IN by)
          (S
            (VP (VBG using)
              (NP
                (NP
                  (NP (JJ mini-osmotic) (NNS pumps))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN model) (NN 2002))
                      (, ,)
                      (NP (NN Alza) (NN Corp))
                      (, ,)
                      (NP (NNP Palo) (NNP Alto))
                      (, ,)
                      (NP (NN CA))
                      (, ,)
                      (NP (NN USA)))
                    (-RRB- -RRB-)))
                (VP (VBN filled)
                  (PP (IN with)
                    (NP
                      (NP (JJ buffered) (NN solution))
                      (VP (VBG containing)
                        (NP
                          (NP
                            (NP
                              (ADJP (CD 200) (NN U/ml))
                              (NN ancrod))
                            (PRN (-LRB- -LRB-)
                              (NP
                                (NP (NN Sigma) (JJ Chemical) (, ,) (JJ St) (NN Louis))
                                (, ,)
                                (NP (NN MO))
                                (, ,)
                                (NP (NN USA)))
                              (-RRB- -RRB-)))
                          (VP (VBN implanted)
                            (PP
                              (ADVP (RB subcutaneously))
                              (NP (CD three) (NNS days))
                              (IN before)
                              (NP
                                (NP (DT the) (NN injection))
                                (PP (IN of)
                                  (NP (NN rTF) (CD -LSB-17) (-RRB- -RSB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Histological) (NN examination))
        (PP (IN of)
          (NP (NNS joints))))
      (VP (VBD was)
        (VP (VBN done)
          (PP (IN after)
            (NP
              (NP (NN paraffin) (NN embedding))
              (, ,)
              (NP
                (ADJP (JJ cutting)))
              (, ,)
              (CC and)
              (NP
                (NP (NN staining))
                (PP (IN with)
                  (NP
                    (NP (NN hematoxylin))
                    (CC and)
                    (NP (NN eosin))))))))))
    (. .)))

(
  (S
    (S
      (NP (PDT All) (DT the) (NNS slides))
      (VP (VBD were)
        (VP
          (VP (VBN coded))
          (CC and)
          (VP (VBN evaluated))
          (ADVP (RB blindly)))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS specimens))
      (VP (VBD were)
        (VP (VBN evaluated)
          (PP (IN with)
            (NP
              (NP (NN respect))
              (PP (TO to)
                (NP
                  (NP
                    (NP (NN occurrence))
                    (PP (IN of)
                      (NP (JJ synovial) (NN hypertrophy))))
                  (, ,)
                  (NP
                    (NP (JJ inflammatory) (NNS cells))
                    (PP (IN in)
                      (NP (JJ synovial) (JJ sublining) (NN compartment))))
                  (, ,)
                  (NP (NN pannus) (NN formation))
                  (CC and)
                  (NP (NN cartilage)
                    (CC and/or)
                    (JJ subchondral) (NN bone) (NN destruction)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Intensity))
        (PP (IN of)
          (NP
            (NP (JJ synovial) (NN inflammation))
            (PRN (-LRB- -LRB-)
              (NP (NN arthritis) (NN index))
              (-RRB- -RRB-)))))
      (VP (VBD was)
        (VP (VBN graded)
          (ADVP (RB arbitrarily))
          (PP (IN from)
            (NP (CD 0) (TO to) (CD 3))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP (JJ immunohistochemical) (NN examination)))
      (, ,)
      (NP (DT the) (JJ knee) (NNS joints))
      (VP (VBD were)
        (VP
          (VP (VBN removed))
          (CC and)
          (VP (VBN demineralized)
            (PP (IN as)
              (NP (VBN described) (NN -LSB-18))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (NP
      (NP (JJ Serial) (NNS cryosections))
      (PP (IN of)
        (NP (CD 6) (JJ μm) (NNS thickness))))
    (VP (VBD were)
      (VP (VBN stained)
        (PP (IN with)
          (NP
            (NP (NN rat) (JJ monoclonal) (NNS antibodies))
            (VP (VBN directed)
              (PP (IN against)
                (NP
                  (NP
                    (NP (NN mouse) (NN CD11b))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NN Mac-1))
                        (: ;)
                        (NP (NN M) (CD 1/70)))
                      (-RRB- -RRB-)))
                  (CC or)
                  (NP
                    (NP (NN CD4))
                    (PRN (-LRB- -LRB-)
                      (NP (NN GK1.5))
                      (-RRB- -RRB-))))))))))))

(
  (S
    (S
      (NP (-LRB- -LRB-)
        (NP (DT both) (NNS antibodies))
        (PP (IN from)
          (NP
            (NP
              (NP (NNP PharMingen) (, ,) (NNP San) (NNP Diego))
              (, ,)
              (NP (NN CA)))
            (, ,)
            (NP (NNP USA))))
        (-RRB- -RRB-))
      (, ,)
      (ADVP (RB then))
      (VP (VBN incubated)
        (PP (IN with)
          (NP
            (NP
              (NP (VBN biotinylated) (JJ secondary) (NNS antibodies))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN DAKO) (NN A/S))
                  (, ,)
                  (NP (NNP Gosulp) (, ,) (NNP Denmark)))
                (-RRB- -RRB-)))
            (CC and)
            (NP
              (NP (NN avidin-biotin-peroxidase) (NNS complexes))
              (PRN (-LRB- -LRB-)
                (NP (NN ABC))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS sections))
      (VP (VBD were)
        (ADJP (JJ counterstained)
          (PP (IN with)
            (NP
              (NP (NN Mayer) (POS 's))
              (NN hematoxylin))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (JJ Murine) (NN splenocyte) (NN suspension))
          (PRN (-LRB- -LRB-)
            (NP (NN cell) (NN density) (CD 2) (NN ×) (NN 106/ml))
            (-RRB- -RRB-)))
        (PP (IN in)
          (NP
            (NP (JJ Iscove) (POS 's) (NN medium))
            (VP (VBN supplemented)
              (PP (IN with)
                (NP
                  (NP
                    (ADJP (CD 10) (NN %))
                    (NP
                      (NP (JJ fetal) (NN calf) (NN serum))
                      (PRN (-LRB- -LRB-)
                        (NP (NN FCS))
                        (-RRB- -RRB-))))
                  (, ,)
                  (NP
                    (ADJP (CD 2) (NN nM))
                    (NN L-glutamine))
                  (, ,)
                  (NP (NN mercaptoethanol))
                  (CC and)
                  (NP
                    (ADJP (CD 50) (NN μg/ml))
                    (NN gentamicin))))))))
      (VP (VBD was)
        (VP (VBN stimulated)
          (PP (IN with)
            (NP (NN rTF)))
          (PP (IN at)
            (NP
              (NP (DT a) (JJ final) (NN concentration))
              (PP (IN of)
                (NP (NN 0.1–10) (NN μg/ml))))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP (VBN defined) (NN time) (NNS points)))
      (, ,)
      (NP (NNS supernatants))
      (VP (VBD were)
        (VP (VBN collected)
          (PP (IN for)
            (NP
              (NP (NN determination))
              (PP (IN of)
                (NP
                  (NP
                    (NP (NN cytokine))
                    (CC and)
                    (NP (NN chemokine)))
                  (NNS levels))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Proliferation))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN by)
            (NP
              (NP (DT the) (NN incorporation))
              (PP (IN of)
                (NP
                  (NP
                    (ADJP (NN -LSB-3H) (-RRB- -RSB-) (JJ -thymidine)))
                  (PRN (-LRB- -LRB-)
                    (NP (JJ specific) (NN activity))
                    (, ,)
                    (NP (CD 42) (NN Ci/mmol))
                    (: ;)
                    (NP (NNP Amersham) (NNP International) (, ,) (NNP Buckinghamshire))
                    (, ,)
                    (NP (NN UK))
                    (-RRB- -RRB-))))
              (PP (IN into)
                (NP
                  (NP
                    (NP (NN splenocyte) (NN suspension))
                    (PRN (-LRB- -LRB-)
                      (NP (NN cell) (NN density) (CD 4) (NN ×) (NN 105/ml))
                      (-RRB- -RRB-)))
                  (, ,)
                  (VP (VBN stimulated)
                    (PP (IN for)
                      (NP (CD 72) (NNS hours)))
                    (PP (IN with)
                      (NP (CC either)
                        (NP (NN rTF))
                        (CC or)
                        (NP
                          (NP (NN LPS))
                          (PP (IN at)
                            (NP
                              (NP (DT a) (JJ final) (NN concentration))
                              (PP (IN of)
                                (NP (CD 0.1–10) (NN μg/ml))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS results))
      (VP (VBD were)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT a) (NN stimulation) (NN index))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NNS counts))
                  (PP (IN per)
                    (NP (NN minute))))
                (, ,)
                (NP (NN mean) (NN ±) (JJ standard) (NN deviation))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN level))
        (PP (IN of)
          (NP
            (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -6))
            (PP (IN in)
              (NP (DT the) (JJ rTF-stimulated) (NNS supernatants))))))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN by)
            (NP
              (NP (DT a) (NN bioassay))
              (VP (VBG measuring)
                (NP
                  (NP (DT the) (NN effect))
                  (PP (IN of)
                    (NP (NN test) (NNS samples)))
                  (PP (IN on)
                    (NP
                      (NP (DT the) (NN growth))
                      (PP (IN of)
                        (NP (DT the)
                          (NP (JJ IL-6-dependent) (NN cell) (NN line))
                          (NP (NN B13.29) (NN -LSB-19))))))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS results))
      (VP (VBD were)
        (VP
          (VP (VBN analyzed)
            (PP (IN by)
              (NP
                (NP (NN incorporation))
                (PP (IN of)
                  (NP
                    (NP
                      (ADJP (NN -LSB-3H) (-RRB- -RSB-) (JJ -thymidine)
                        (PP (IN after)
                          (NP (CD 72) (NNS hours)))))
                    (NN stimulation))))))
          (CC and)
          (VP (VBN compared)
            (PP (TO to)
              (NP
                (NP (NNS results))
                (PP (IN with)
                  (NP
                    (NP (DT the) (JJ standard) (NNS dilutions))
                    (PP (IN of)
                      (NP
                        (NP (JJ recombinant) (NN mouse) (NN IL-6))
                        (PRN (-LRB- -LRB-)
                          (NP (NN Genzyme))
                          (, ,)
                          (NP (NN Cambridge))
                          (, ,)
                          (NP
                            (NP (NN MA))
                            (, ,)
                            (NP (NN USA)))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS levels))
        (PP (IN of)
          (NP
            (NP (NN macrophage) (JJ inflammatory) (NN protein) (-LRB- -LRB-) (NN MIP) (-RRB- -RRB-) (CD -1α))
            (CC and)
            (NP
              (NP (NN RANTES))
              (-LRB- -LRB-)
              (VP (VBN regulated)
                (PP (IN on)
                  (NP
                    (NP (NN activation) (JJ normal) (NN T-cell))
                    (VP
                      (VP (VBN expressed))
                      (CC and)
                      (VP (VBN secreted))))))
              (-RRB- -RRB-)))))
      (VP (VBD were)
        (VP
          (VP (VBN measured)
            (PP (IN by)
              (NP
                (NP (DT an) (JJ enzyme-linked) (JJ immunosorbent) (NN assay))
                (VP (VBG using)
                  (NP
                    (NP (NN Quantikine) (NN M) (NNS kits))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NN R&D) (NNS Systems))
                        (, ,)
                        (NP
                          (NP (NNP Minneapolis))
                          (, ,)
                          (NP (NN MN))
                          (, ,)
                          (NP (NNP USA))))
                      (-RRB- -RRB-)))))))
          (CC and)
          (VP (VBN expressed)
            (PP (IN in)
              (NP (NN pg/ml)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS differences))
        (PP (IN in)
          (NP
            (NP (DT the)
              (NP (NN incidence))
              (CC and)
              (NP
                (NP (DT the) (NN severity))
                (PP (IN of)
                  (NP (NN arthritis)))))
            (PP (IN in)
              (NP (DT the) (NNS groups))))))
      (VP (VBD were)
        (VP (VBN analyzed)
          (PP (IN by)
            (NP
              (NP
                (NP (DT the) (NN Fisher) (POS 's))
                (NN test))
              (CC and)
              (NP (NN Mann–Whitney) (NN U) (NN test))))
          (, ,)
          (ADVP (RB respectively)))))
    (. .)))

(
  (S
    (NP (NNS Results))))

(
  (S
    (S
      (NP
        (NP (DT The) (NN ability))
        (PP (IN of)
          (NP (NN rTF)))
        (VP (TO to)
          (VP (VB induce)
            (NP (NN arthritis)))))
      (VP (VBD was)
        (VP (VBN evaluated)
          (PP (IN by)
            (NP
              (NP (NN injection))
              (PP (IN of)
                (NP
                  (NP (NN rTF))
                  (PP (IN in)
                    (NP
                      (NP
                        (NP (DT the) (NNS doses))
                        (NP
                          (QP (CD 0.2) (, ,) (CD 2.0) (, ,)
                            (CC and)
                            (CD 20))
                          (NN μg)))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (QP (CD 0.004) (, ,) (CD 0.04) (, ,)
                            (CC and)
                            (CD 0.4))
                          (NN nmol))
                        (-RRB- -RRB-))))))
              (PP (IN into)
                (NP
                  (NP (DT the) (JJ knee) (NN joint))
                  (PP (IN of)
                    (NP (NN NMRI) (NNS mice))))))))))
    (. .)))

(
  (S
    (PP
      (NP (CD Four) (NNS days))
      (IN after)
      (NP (DT the) (NN inoculation)))
    (, ,)
    (NP
      (NP
        (NP (JJ morphological) (NNS signs))
        (PP (IN of)
          (NP (NN arthritis))))
      (-LRB- -LRB-)
      (NP (JJ synovial) (NN tissue) (NN hypertrophy))
      (, ,)
      (CC and)
      (NP (JJ inflammatory) (NN cell) (NNS infiltrates))
      (-RRB- -RRB-))
    (VP (VBD were)
      (VP (VBN found)
        (PP (IN in)
          (NP
            (NP
              (NP (CD 33) (NN %))
              (, ,)
              (NP (CD 56) (NN %))
              (CC and)
              (NP (CD 83) (NN %)))
            (PP (IN of)
              (NP (NNS joints)))))
        (, ,)
        (ADVP (RB respectively))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Control) (NNS mice))
        (VP (VBN injected)
          (PP (IN with)
            (NP
              (NP (DT the) (NN amount))
              (PP (IN of)
                (NP (NN LPS)))
              (ADJP (JJ equivalent)
                (PP (TO to)
                  (NP
                    (NP (PRP$ its) (NN concentration))
                    (PP (IN in)
                      (NP (DT the) (NN rTF) (NN preparation))))))))))
      (VP (VBD exhibited)
        (NP (NN arthritis))
        (PP
          (ADVP (RB only))
          (IN in)
          (NP
            (NP (CD 28) (NN %))
            (PP (IN of)
              (NP
                (NP (NNS cases))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN 13/15))
                    (CC versus)
                    (NP (NN 4/14)))
                  (: ;)
                  (NP (NN P) (NN <) (CD 0.01))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN arthritis) (NN index))
        (PP (IN of)
          (NP (DT the) (JJ rTF-induced) (NN arthritis))))
      (VP (VBD was)
        (ADJP
          (ADJP (RB significantly) (JJR higher))
          (PP (IN in)
            (NP
              (NP (NNS joints))
              (VP (VBN injected)
                (PP (IN with)
                  (NP
                    (NP (CD 20) (NN μg))
                    (PP (IN of)
                      (NP (NN rTF))))))))
          (PP (IN than)
            (PP (IN in)
              (NP
                (NP (DT the) (NNS controls))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (CD 1.73)
                      (CC versus)
                      (CD 0.23))
                    (: ;)
                    (NP (NN P) (JJ <) (CD 0.01)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (ADVP (RB Moreover))
    (, ,)
    (NP
      (NP (CD 6/13) (NNS joints))
      (VP (VBN injected)
        (PP (IN with)
          (NP
            (NP (CD 20) (NN μg))
            (PP (IN of)
              (NP (NN rTF)))))))
    (VP (VBD developed)
      (NP
        (NP (JJ extrasynovial) (NNS features))
        (PP (IN of)
          (NP
            (NP (NN arthritis))
            (PRN (-LRB- -LRB-)
              (NP (NN pannus) (NN formation))
              (, ,)
              (NP (NN n) (JJ =) (CD 2))
              (: ;)
              (NP
                (NP (NN cartilage) (NN destruction))
                (, ,)
                (NP (NN n) (JJ =) (CD 3))
                (CC and)
                (NP (JJ periarticular) (NN bone) (NN destruction)))
              (, ,)
              (NP (NN n) (JJ =) (CD 1))
              (-RRB- -RRB-)))))
      (PP (VBN compared)
        (PP (TO to)
          (NP
            (NP (RB only) (CD one))
            (PP (IN in)
              (NP (DT the) (NN control) (NN group)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT all) (JJ further) (NNS experiments)))
      (NP
        (NP (DT the) (NN dose))
        (PP (IN of)
          (NP
            (NP (CD 20) (NN μg))
            (PP (IN of)
              (NP (NN TF)))))
        (PP (IN per)
          (NP (NN knee))))
      (VP (VBD was)
        (VP (VBN used))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Dynamics))
        (PP (IN of)
          (NP (JJ rTF-induced) (NN arthritis))))
      (VP (VBD were)
        (VP (VBN assessed)
          (ADVP (RB morphologically))
          (PP (IN on)
            (NP
              (NP
                (NP (NNS days)
                  (QP (CD 4) (, ,) (CD 14)))
                (CC and)
                (NP (CD 60)))
              (PP (IN after)
                (NP (DT the) (NN rTF) (NN injection))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP
            (NP (DT The) (JJS highest) (NN frequency))
            (PP (IN of)
              (NP (NN arthritis))))
          (CC and)
          (NP
            (NP (NN severity))
            (PP (IN of)
              (NP (NN inflammation)))))
        (VP (VBD was)
          (VP (VBN observed)
            (PP (IN on)
              (NP (NN day) (CD 4)))
            (PP (IN after)
              (NP (NN injection))))))
      (CC and)
      (S
        (NP (PRP it))
        (VP (VBD diminished)
          (ADVP (RB significantly))
          (PP (IN by)
            (NP (NNS days) (CD 14)
              (CC and)
              (CD 60)))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN 13/15))
              (CC versus)
              (NP (CD 2/8)
                (CC and)
                (CD 2/6)))
            (, ,)
            (NP (NN P) (NN <) (CD 0.05))
            (: ;)
            (NP (NNP Fig.) (NN 1a))
            (, ,)
            (NP (NN b))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Notably))
      (, ,)
      (NP
        (NP (NN erosion))
        (CC and/or)
        (NP (NN pannus) (NN formation)))
      (VP (VBD were)
        (ADVP (RB always))
        (VP (VBN found)
          (PP
            (PP (IN in)
              (NP
                (NP (NNS cases))
                (PP (IN of)
                  (NP (JJ long) (JJ lasting) (NN arthritis)))))
            (CC but)
            (PP (IN in)
              (NP
                (NP (NN none))
                (PP (IN of)
                  (NP (DT the) (NNS controls)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Sensitivity))
        (PP (TO to)
          (NP (NN rTF))))
      (VP (VBD varied)
        (PP (IN between)
          (NP (DT the) (JJ healthy) (NN mouse) (NNS strains)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (CD Four) (NNS days))
          (PP (IN after)
            (NP
              (NP (DT the) (NN injection))
              (PP (IN of)
                (NP
                  (NP (NN rTF))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 20) (NN μg/knee))
                    (-RRB- -RRB-))))
              (PP (IN into)
                (NP
                  (NP (NN NMRI))
                  (PRN (-LRB- -LRB-)
                    (NP (NN n) (JJ =) (CD 15))
                    (-RRB- -RRB-)))))))
        (, ,)
        (NP
          (NP (CD CB17)
            (PRN (-LRB- -LRB-)
              (NP (NN n) (JJ =) (CD 8))
              (-RRB- -RRB-))
            (CC and)
            (NN BALB/c) (NNS mice))
          (PRN (-LRB- -LRB-)
            (NP (NN n) (JJ =) (CD 8))
            (-RRB- -RRB-)))
        (, ,)
        (NP
          (NP (JJ morphological) (NNS signs))
          (PP (IN of)
            (NP (NN arthritis)))))
      (VP (VBD were)
        (VP (VBN registered)
          (PP (IN in)
            (NP
              (NP
                (NP (CD 80) (NN %))
                (, ,)
                (NP (CD 75) (NN %))
                (CC and)
                (NP (CD 50) (NN %)))
              (PP (IN of)
                (NP (JJ knee) (NNS joints)))
              (, ,)
              (ADVP (RB respectively)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP indicate)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN susceptibility))
              (PP (TO to)
                (NP
                  (NP (JJ inflammatory) (NN potential))
                  (PP (IN of)
                    (NP (NN rTF))))))
            (VP (VBZ is)
              (ADJP (JJ dependent)
                (PP (IN on)
                  (NP
                    (NP (JJ genetic) (NN background))
                    (PP (IN of)
                      (NP (DT the) (NN host)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Immunochemical) (NN staining))
        (PP (IN of)
          (NP (NN joint) (NNS sections))))
      (VP (VBD revealed)
        (NP
          (NP (JJ dense) (NNS infiltrates))
          (VP (VBG consisting)
            (PP (IN of)
              (NP
                (NP (JJ Mac-1+) (JJ mononuclear) (NNS cells))
                (PP (IN in)
                  (NP (DT the) (JJ synovial) (NN tissue)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP (PDT all) (DT the) (NNS sections))
      (VP (VBD were)
        (ADJP (JJ negative)
          (PP (IN for)
            (S
              (VP (VBG staining)
                (PP (IN with)
                  (NP (JJ CD4-specific) (NNS antibodies)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBD allowed)
        (S
          (NP (PRP us))
          (VP (TO to)
            (VP (VB conclude)
              (SBAR (IN that)
                (S
                  (NP
                    (NP (DT the) (JJ inflammatory) (NN infiltrate))
                    (VP (VBN observed)
                      (PP (IN after)
                        (NP
                          (NP (DT the) (NN injection))
                          (PP (IN of)
                            (NP (NN rTF)))))))
                  (VP (VBD consisted)
                    (ADVP (RB predominantly))
                    (PP (IN of)
                      (NP
                        (NP (NNS macrophages))
                        (VP (VBN accompanied)
                          (PP (IN by)
                            (NP
                              (NP (JJ few))
                              (PP (IN if)
                                (NP
                                  (NP (DT any) (NNS neutrophils))
                                  (PRN (-LRB- -LRB-)
                                    (NP (NNP Fig.) (CD 2))
                                    (-RRB- -RRB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB evaluate)
            (NP
              (NP (DT the) (NN role))
              (PP (IN of)
                (NP (JJ different) (JJ immune) (NNS cells)))
              (PP (IN in)
                (NP
                  (NP (DT the) (NN development))
                  (PP (IN of)
                    (NP (JJ rTF-induced) (NN inflammation)))))))))
      (, ,)
      (NP (NN cell) (NN depletion) (NNS procedures))
      (VP (VBD were)
        (VP (VBN performed))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Mice))
      (VP (VBN pretreated)
        (PP (IN with)
          (NP (VBG lysing)
            (NP (JJ antineutrophil) (NNS antibodies))))))
    (VP (VBD showed)
      (NP
        (NP (DT no) (NN reduction))
        (PP (IN in)
          (NP
            (NP (DT the)
              (NP (NN frequency))
              (CC or)
              (NP (NN intensity)))
            (PP (IN of)
              (NP (NN arthritis))))))
      (VP (VBD compared)
        (PP (TO to)
          (NP
            (NP (NNS controls))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (VBD received)
                  (NP
                    (NP (NN antiovalbumin) (NNS antibodies))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NN 5/8))
                        (CC versus)
                        (NP
                          (ADJP (JJ 7/8)))
                        (, ,)
                        (ADVP (RB respectively)))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Mice))
        (VP (VBN injected)
          (PP (IN with)
            (NP
              (NP (NN etoposide))
              (, ,)
              (CONJP (CC and)
                (RB thereby))
              (VP (VBN deprived)
                (PP (IN of)
                  (NP (NN monocyte/macrophage) (NN cell) (NN population))))
              (, ,)))))
      (VP (VBD demonstrated)
        (NP
          (NP (DT a) (NN tendency))
          (PP (TO to)
            (NP
              (NP (DT a) (NN reduction))
              (PP (IN in)
                (NP
                  (NP (NN frequency))
                  (CONJP (CC but)
                    (RB not))
                  (NP
                    (NP (DT the) (NN severity))
                    (PP (IN of)
                      (NP (NN arthritis)))))))))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (NN 6/8))
            (CC versus)
            (NP (NN 4/7)))
          (: ;)
          (NP
            (NP (RB not) (JJ significant))
            (: ;)
            (NP (NNP Fig.) (CD 3)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Intra-articular) (NN injection))
        (PP (IN of)
          (NP (NN rTF)))
        (PP (IN into)
          (NP
            (NP (NN SCID) (NNS mice))
            (ADJP (JJ deficient)
              (PP (IN for)
                (NP
                  (NP (NN T-))
                  (CC and)
                  (NP (NNS B-lymphocytes))))))))
      (VP (VBD revealed)
        (NP (DT no) (NN difference))
        (PP (IN in)
          (NP
            (NP (DT the) (NN frequency))
            (PP (IN of)
              (NP (NN arthritis)))))
        (PP (VBN compared)
          (PP (TO to)
            (NP
              (NP (JJ congenic)
                (NP (CD CB17) (NNS mice))
                (NN strain))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN 11/15))
                  (CC versus)
                  (NP (NN 12/15)))
                (, ,)
                (FRAG
                  (ADVP (RB not))
                  (ADJP (JJ significant)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS results))
        (PP (IN of)
          (NP (NNS experiments))))
      (VP (VBD indicated)
        (SBAR (IN that)
          (S
            (NP
              (NP (VBN isolated) (NN depletion))
              (PP (IN of)
                (NP (CC neither)
                  (NP (NN monocyte))
                  (CC nor)
                  (NP (NN lymphocyte) (NN cell) (NNS populations)))))
            (VP (VBD was)
              (S
                (ADVP (RB enough))
                (VP (TO to)
                  (VP (VB abolish)
                    (NP
                      (NP (DT the) (NN induction))
                      (PP (IN of)
                        (NP (JJ rTF-induced) (NN arthritis))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB test)
            (SBAR (IN if)
              (S
                (NP (DT a) (JJ combined) (NN lymphocyte)
                  (CC and)
                  (NN monocyte) (NN cell) (NN depletion))
                (VP (VBD was)
                  (ADJP (JJ efficient)
                    (PP (IN in)
                      (NP
                        (NP (NN prevention))
                        (PP (IN of)
                          (NP (JJ rTF-induced) (NN cell) (NN infiltration))))))))))))
      (, ,)
      (NP
        (NP (NN SCID) (NNS mice))
        (VP (VBN treated)
          (PP (IN with)
            (NP (NN etoposide)))))
      (VP (VBD were)
        (ADVP (RB intra-articularly))
        (VP (VBN injected)
          (PP (IN with)
            (NP (NN rTF))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (QP (RB Only) (CD one) (IN of) (CD seven))
          (NNS mice))
        (PP (IN in)
          (NP (DT this) (NN group))))
      (VP (VBD developed)
        (NP (NN arthritis))
        (PP (IN in) (NN response) (TO to)
          (NP
            (NP (NN injection))
            (PP (IN of)
              (NP (NN rTF)))))
        (, ,)
        (S
          (VP (VBG demonstrating)
            (SBAR (IN that)
              (S
                (NP
                  (NP (NN interaction))
                  (PP (IN between)
                    (NP
                      (NP (NNS macrophages))
                      (CC and)
                      (NP (NNS lymphocytes)))))
                (VP (VBZ is)
                  (ADJP (JJ essential)
                    (PP (IN for)
                      (NP
                        (NP (JJ cellular) (NN infiltration))
                        (PP (IN of)
                          (NP
                            (NP (NN synovium))
                            (PP (VBG following)
                              (NP
                                (NP (NN rTF) (NN injection))
                                (PRN (-LRB- -LRB-)
                                  (NP (NNP Fig.) (CD 3))
                                  (-RRB- -RRB-))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Systemic) (NN depletion))
        (PP (IN of)
          (NP (NN fibrinogen)))
        (PP (IN with)
          (NP (NN ancrod)))
        (ADVP
          (ADVP (RB prior))
          (PP (TO to)
            (NP (NN rTF) (NN injection)))))
      (VP (VBD did) (RB not)
        (VP (VB reduce)
          (NP
            (NP (DT the) (NN incidence))
            (PP (IN of)
              (NP (JJ rTF-induced) (NN arthritis)))
            (PP (IN in)
              (NP (NN 6/8) (NN NMRI) (NNS mice)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Effects))
        (PP (IN of)
          (NP (NN rTF)))
        (PP (IN on)
          (NP (JJ lymphoid) (NNS cells))))
      (VP (VBD were)
        (VP (VBN investigated)
          (PP (IN by)
            (S
              (VP (VBG incubating)
                (NP (NN mouse) (NNS splenocytes))
                (PP (IN with)
                  (NP
                    (NP (NN rTF))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (CD 0.1) (NN μg/ml))
                        (, ,)
                        (NP (CD 1) (NN μg/ml))
                        (, ,)
                        (NP (CD 5) (NN μg/ml))
                        (, ,)
                        (CC or)
                        (NP (CD 10) (NN μg/ml)))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Investigation))
        (PP (IN of)
          (NP
            (NP (NNS supernatants))
            (PP (IN after)
              (NP
                (NP (CD 48) (NNS hours))
                (PP (IN of)
                  (NP
                    (NP (NN stimulation))
                    (PP (IN for)
                      (NP
                        (NP (DT the) (NN level))
                        (PP (IN of)
                          (NP
                            (NP (NN IL-6))
                            (, ,)
                            (NP (NN RANTES))
                            (, ,)
                            (CC and)
                            (NP (NN MIP-1α)))))))))))))
      (VP (VBD demonstrated)
        (NP
          (NP (DT a) (JJ dose-dependent) (NN increase))
          (PP (IN in)
            (NP
              (NP (DT the) (NN level))
              (PP (IN of)
                (NP (NNS chemokines))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN increase))
      (VP
        (VP (VBD was)
          (ADJP (JJ pronounced)
            (PP (IN for)
              (NP (NN MIP-1α))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP
                (NP (CD 73) (NN ±) (CD 33) (NN pg/ml))
                (PP (IN in)
                  (NP (JJ non-stimulated) (NNS cells))))
              (CC versus)
              (NP
                (NP
                  (QP (CD 139) (NN ±) (CD 32))
                  (NN pg/ml))
                (PP (IN after)
                  (NP
                    (NP (NN stimulation))
                    (PP (IN with)
                      (NP
                        (NP (CD 5) (NN μg/ml))
                        (PP (IN of)
                          (NP (NN rTF)))))))))
            (: ;)
            (S
              (NP (NN n))
              (VP (JJ =)
                (NP (CD 3))))
            (-RRB- -RRB-)))
        (CC but)
        (VP (VBD was)
          (ADJP (RB only) (JJ marginal)
            (PP (IN for)
              (NP (NN RANTES))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP
                (QP (CD 256) (NN ±) (CD 46))
                (NN pg/ml))
              (CC versus)
              (NP
                (QP (CD 365) (NN ±) (CD 32))
                (NN pg/ml)))
            (: ;)
            (S
              (NP (NN n))
              (VP (JJ =)
                (NP (CD 3))))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP (CC neither)
        (NP
          (NP (NN change))
          (PP (IN in)
            (NP
              (NP (DT the) (NN level))
              (PP (IN of)
                (NP (NN IL-6))))))
        (CC nor)
        (NP
          (NP (NN proliferation))
          (PP (IN of)
            (NP (NNS lymphocytes)))))
      (VP (VBD was)
        (VP (VBN observed))))
    (. .)))

(
  (S
    (NP (NN Discussion))))

(
  (S
    (S
      (NP
        (NP (NN Inflammation))
        (CC and)
        (NP (NN thrombosis)))
      (VP (VBP are)
        (VP (VBN linked)
          (PP (IN in)
            (NP (JJ many) (JJ clinical) (NNS conditions))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ is)
        (VP (VBN presumed)
          (SBAR (IN that)
            (S
              (NP (JJ proinflammatory) (NNS mediators))
              (VP (VB potentiate)
                (NP
                  (NP (NN activation))
                  (PP (IN of)
                    (NP
                      (NP (NN blood) (NN coagulation))
                      (CC and)
                      (NP
                        (NP
                          (NP (NN serine) (NNS proteases))
                          (PP (IN of)
                            (NP (DT the) (NN coagulation) (NN system))))
                        (, ,)
                        (NP
                          (NP (RB especially) (DT the) (JJ terminal) (NN enzyme) (NN thrombin))
                          (, ,)
                          (VP (VBN known)
                            (PP (IN for)
                              (NP
                                (NP
                                  (ADJP
                                    (ADJP (JJ proinflammatory))
                                    (CC and)
                                    (ADJP (JJ mitogenic/chemotactic)))
                                  (NNS effects))
                                (PP (CC both)
                                  (PP (IN in)
                                    (NP (NN circulation)))
                                  (CC and)
                                  (PP (RB locally) (IN in)
                                    (NP (JJ synovial) (NN tissue) (CD -LSB-20-22)))
                                  (-RRB- -RSB-))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT An) (NN indication))
        (PP (IN of)
          (NP
            (NP (DT the) (NN importance))
            (PP (IN of)
              (NP (NN TF)))
            (PP (IN in)
              (NP (DT the) (JJ inflammatory) (NN process))))))
      (VP (VBD was)
        (VP (VBN obtained)
          (PP (IN in)
            (NP
              (NP (DT the) (JJ animal) (NN model))
              (PP (IN of)
                (NP (NN sepsis)))
              (, ,)
              (SBAR
                (WHPP (IN in)
                  (WHNP (WDT which)))
                (S
                  (NP (JJ TF-dependent) (NN procoagulant) (NN activity))
                  (VP (VBD correlated)
                    (PP (IN with)
                      (NP
                        (NP (DT the) (NN level))
                        (PP (IN of)
                          (NP
                            (NP (NN tumor) (NN necrosis))
                            (ADJP (JJ factor-α)
                              (NP (CD -LSB-23))))))))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP
        (NP (NN modulation))
        (PP (IN of)
          (NP (JJ TF-dependent) (NN coagulation)))
        (PP (IN by)
          (NP
            (NP (NN administration))
            (PP (IN of)
              (NP (CC either)
                (NP (NN TF-pathway) (NN inhibitor))
                (CC or)
                (NP (NN anti-TF) (NNS antibodies)))))))
      (VP
        (VP (VBD decreased)
          (NP
            (NP (JJ circulating) (NNS levels))
            (PP (IN of)
              (NP
                (NP (NN IL-6))
                (CC and)
                (NP (NN IL-8) (CD -LSB-24,25) (-RRB- -RSB-))))))
        (, ,)
        (CC and)
        (VP (VBD diminished)
          (NP
            (NP (NN proliferation))
            (CC and)
            (NP (JJ perivascular) (NN cell) (NN infiltration) (CD -LSB-26,27)))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN study))
      (VP (VBZ shows)
        (SBAR (IN that)
          (S
            (NP (DT the) (NN TF) (NN molecule))
            (VP (VBZ possesses)
              (NP (JJ strong) (JJ proinflammatory) (NNS properties))
              (, ,)
              (S
                (VP (VBG causing)
                  (NP (NN arthritis)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Histological) (NN analysis))
      (VP (VBD revealed)
        (SBAR (IN that)
          (S
            (NP (JJ TF-induced) (NN synovitis))
            (VP (MD could)
              (VP (VB be)
                (VP (VBN attributed)
                  (ADVP (RB mostly))
                  (PP (TO to)
                    (NP (JJ infiltrating) (NNS macrophages))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Mononuclear) (NN cell) (NN influx))
        (PP (IN into)
          (NP (NN synovia))))
      (VP (VBZ is)
        (NP
          (NP (DT an) (JJ early) (NN finding))
          (PP (IN in)
            (NP
              (NP (DT the) (NN majority))
              (PP (IN of)
                (NP (JJ asymptomatic) (NNS subjects))))))
        (, ,)
        (S
          (VP (VBG preceding)
            (NP
              (NP
                (ADJP (RB clinically) (JJ overt))
                (NN arthritis))
              (PP (IN in)
                (NP (NN RA) (CD -LSB-28,29) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Furthermore))
      (, ,)
      (NP (JJ synovial) (NN macrophage) (NN infiltration))
      (VP
        (VP (VBZ is)
          (NP
            (NP (DT a) (JJ characteristic) (NN feature))
            (PP (IN of)
              (NP
                (ADJP (CC both)
                  (ADJP (JJ autoimmune))
                  (CC and)
                  (ADJP (JJ bacterial)))
                (NN arthritis) (CD -LSB-30,31) (-RRB- -RSB-)))))
        (CC and)
        (VP (VBZ is)
          (NP
            (NP (DT a) (NN determinant))
            (PP (IN of)
              (NP (NN joint) (NNS erosions) (CD -LSB-32,33))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NN observation))
      (, ,)
      (PP (IN in)
        (NP
          (NP (NN combination))
          (PP (IN with)
            (NP
              (NP (DT an) (VBN increased) (JJ TF-dependent) (NN procoagulant) (NN activity))
              (PP (IN in)
                (NP
                  (NP
                    (NP (NN blood))
                    (CC and)
                    (NP (JJ synovial) (NN fluid)))
                  (PP (IN of)
                    (NP
                      (NP (NNS patients))
                      (PP (IN with)
                        (NP (NN RA)))))))))))
      (, ,)
      (VP (VBZ implies)
        (NP
          (NP (NN participation))
          (PP (IN of)
            (NP (NN TF)))
          (PP
            (PP (IN in)
              (S
                (VP (VBG triggering)
                  (NP
                    (NP (DT the) (JJ initial) (NNS steps))
                    (PP (IN of)
                      (NP (NN inflammation))))
                  (PP (IN during)
                    (NP (NN RA))))))
            (CC and/or)
            (PP (IN in)
              (S
                (VP (VBG rendering)
                  (NP (DT the) (NN inflammation) (JJ chronic)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Composition))
        (PP (IN of)
          (NP
            (NP (JJ inflammatory) (NN infiltrate))
            (CC and)
            (NP (NN cell) (NN depletion) (NNS studies)))))
      (VP (VBD showed)
        (SBAR (IN that)
          (S
            (NP (NN TF))
            (VP (VBZ exerts)
              (NP (PRP$ its) (JJ proinflammatory) (NNS properties))
              (PP (IN in)
                (NP
                  (NP (DT a) (JJ cell-specific) (NN manner))
                  (VP (VBG targeting)
                    (NP (DT the) (NN macrophage/) (NN monocyte) (NN population))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBZ is) (RB not)
        (ADJP (JJ surprising))
        (S
          (VP (VBG taking)
            (PP (IN into)
              (NP (NN consideration)))
            (SBAR (IN that)
              (S
                (NP (NNS macrophages/monocytes))
                (VP (VBP are)
                  (NP
                    (NP (DT the) (JJ only) (NNS cells))
                    (PP (IN in)
                      (NP (DT the) (NN blood) (NN circulation) (NN compartment)))
                    (SBAR
                      (WHNP (WDT which))
                      (S
                        (VP (VBP express)
                          (NP
                            (NP (NN TF))
                            (PP (IN on)
                              (NP (PRP$ their) (NN surface) (CD -LSB-8,34)))))
                        (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Moreover))
      (, ,)
      (NP (PRP we))
      (VP (VBD demonstrated)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT an) (NN interaction))
              (PP (IN between)
                (NP
                  (NP (NNS monocytes))
                  (CC and)
                  (NP (NNS lymphocytes)))))
            (VP (VBD was)
              (NP
                (NP (DT a) (NN prerequisite))
                (PP (IN of)
                  (NP (DT the) (JJ TF-induced) (NN arthritis)))))))))
    (. .)))

(
  (S
    (S
      (NP (VBN Activated) (NN T) (NNS cells))
      (VP (VBD were)
        (ADJP (JJ able)
          (S
            (VP (TO to)
              (VP (VB induce)
                (NP (NN TF) (NN production))
                (PP (IN by)
                  (S
                    (VP (VBG stimulating)
                      (NP (NNS monocytes))
                      (PP (IN through)
                        (NP (NN CD40) (NN ligand) (CD -LSB-35,36) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN mechanism))
      (VP (MD may)
        (VP (VB contribute)
          (PP (TO to)
            (NP
              (NP (DT a) (JJ positive) (NN feedback))
              (ADJP (JJ essential)
                (PP (IN for)
                  (NP
                    (NP (NN maintenance))
                    (PP (IN of)
                      (NP (JJ TF-induced) (NN inflammation)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Interestingly))
      (, ,)
      (NP
        (NP (NNS neutrophils))
        (, ,)
        (NP (JJ other) (JJ principal) (JJ inflammatory) (NNS cells))
        (, ,))
      (VP (VBD were) (RB not)
        (ADJP (JJ sensitive)
          (PP (TO to)
            (NP (NN TF) (NN stimulation))))))
    (: –)
    (S
      (NP (DT these) (NNS cells))
      (VP
        (VP (VBD were)
          (ADVP (RB neither))
          (VP (VBN found)
            (PP (IN in)
              (NP (JJ synovial) (NNS tissues)))))
        (CC nor)
        (VP (VBD affected)
          (NP (NN arthritis) (NN frequency))
          (PP (IN in)
            (NP (DT the) (NN depletion) (NNS experiments))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Mononuclear) (NNS cells))
        (VP (VBG composing)
          (NP
            (NP (DT the) (JJ inflammatory) (NN infiltrate))
            (PP (IN in)
              (NP (NN synovia))))))
      (VP (VBD were)
        (ADVP (RB mostly))
        (NP (JJ Mac-1+) (JJ CD4-) (NNS cells))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Abundant) (NN expression))
        (PP (IN of)
          (NP (NN Mac-1) (NN molecule)))
        (PP (IN on)
          (NP (DT the) (NN monocyte) (NN surface))))
      (VP (VBZ indicates)
        (NP
          (NP (DT a) (JJ principal) (NN role))
          (PP (IN of)
            (NP (NN β2-integrins)))
          (PP (IN in)
            (NP
              (NP (NN cell) (NN activation))
              (PP (VBG following)
                (NP
                  (NP (NN exposure))
                  (PP (TO to)
                    (NP (NN TF))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD Two) (NNS methods))
        (PP (IN of)
          (NP (JJ such) (NN activation))))
      (VP (MD may)
        (VP (VB be)
          (VP (VBN considered)))))
    (. .)))

(
  (S
    (S
      (NP (NN TF))
      (VP (MD may)
        (VP (VB attract)
          (NP (NN Mac-1+) (NNS cells))
          (PP
            (ADVP (RB indirectly))
            (IN by)
            (S
              (VP (VBG increasing)
                (NP
                  (NP (NN formation))
                  (PP (IN of)
                    (NP
                      (NP (NN coagulation) (NNS proteins))
                      (VP (VBN known)
                        (PP (IN as)
                          (NP
                            (NP (NN Mac-1) (NNS ligands))
                            (, ,)
                            (PP (FW e.g.))))))))))))))
    (. .)))

(
  (S
    (NP
      (NP
        (NP (NN Factor) (NN X))
        (CC and)
        (NP (NN fibrinogen)))
      (. .))))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP
        (NP (DT the) (JJ high) (NN incidence))
        (PP (IN of)
          (NP (JJ TF-induced) (NN arthritis)))
        (PP (IN in)
          (NP (JJ defibrinated) (NNS mice))))
      (VP (VBZ favors)
        (NP
          (NP (DT a) (JJ direct) (JJ stimulatory) (NN effect))
          (PP (IN of)
            (NP (NN TF)))
          (PP (IN on)
            (NP (JJ sensitive) (NNS cells))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Treatment))
        (PP (IN of)
          (NP (NNS macrophages)))
        (PP (IN with)
          (NP (NN TF)))
        (ADVP (FW in) (FW vitro)))
      (VP
        (VP (VBZ has)
          (VP (VBN been)
            (VP (VBN shown)
              (S
                (VP (TO to)
                  (VP (VB increase)
                    (NP
                      (NP (DT the) (NN expression))
                      (PP (IN of)
                        (NP
                          (NP (JJ β2-chain-containing) (NN adhesion) (NNS molecules))
                          (NP (CD -LSB-37) (-RRB- -RSB-)))))))))))
        (CC and)
        (VP (VBZ supports)
          (NP
            (NP (DT the) (NN idea))
            (PP (IN of)
              (NP (JJ direct) (JJ TF-induced) (NN Mac-1) (NN expression)))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Lack))
      (PP (IN of)
        (NP
          (NP (JJ CD4+) (NNS cells))
          (ADJP (JJ responsible)
            (PP (IN for)
              (NP
                (NP (NN peptide) (NN presentation))
                (PP (IN through)
                  (NP (NN MHC) (NN class) (CD II) (NNS molecules)))))))))
    (VP (VBZ shows)
      (SBAR (IN that)
        (S
          (NP (DT this) (NN mechanism))
          (VP (VBZ is) (RB not)
            (ADJP (JJ compulsory)
              (PP (IN for)
                (NP (JJ TF-induced) (JJ synovial) (NN infiltration))))
            (, ,)
            (PP (IN in) (NN contrast) (TO to)
              (NP (JJ experimental) (NN glomerulonephritis)))
            (SBAR
              (WHADVP (WRB where))
              (S
                (NP
                  (NP (JJ simultaneous) (NN expression))
                  (PP (IN of)
                    (NP
                      (NP (NN TF))
                      (CC and)
                      (NP (NN MHC) (NN class) (CD II) (NNS molecules)))))
                (VP (VBD was)
                  (VP
                    (VP (VBN observed))
                    (CC and)
                    (VP
                      (ADVP (RB efficiently))
                      (VBN blocked)
                      (PP (IN by)
                        (NP (NN anti-TF) (NNS antibodies) (CD -LSB-38,39) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN way))
        (SBAR
          (WHPP (IN in)
            (WHNP (WDT which)))
          (S
            (NP (NN TF))
            (VP (VBZ interacts)
              (PP (IN with)
                (NP (NNS macrophages)))))))
      (VP (VBZ is) (RB not)
        (ADJP (JJ clear))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Exposure))
        (PP (IN of)
          (NP (NN spleen) (NN cell) (NNS cultures)))
        (PP (TO to)
          (NP (NN TF))))
      (VP (VBD did) (RB not)
        (VP (VB induce)
          (NP
            (NP (DT the) (NN release))
            (PP (IN of)
              (NP (JJ proinflammatory) (NNS cytokines)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VB favor)
        (NP (DT the) (NN suggestion)
          (SBAR (IN that)
            (S
              (NP (NN TF))
              (VP
                (VP (VBZ acts)
                  (ADVP (RB directly))
                  (PP (IN on)
                    (NP (JJ inflammatory) (NNS cells))))
                (CC and)
                (VP
                  (ADVP (RB not))
                  (PP (IN by)
                    (NP (DT a) (JJ cytokine-mediated) (NN mechanism))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ TF-mediated) (NN release))
        (PP (IN of)
          (NP (NN chemoattractant) (NNS molecules)))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VB recruit)
              (NP
                (NP (JJ inflammatory) (NNS cells))
                (PP (IN from)
                  (NP
                    (NP (DT the) (NN circulation))
                    (CC or)
                    (NP (JJ surrounding) (NNS tissues))))))))
        (, ,))
      (VP (VBZ is)
        (NP (DT an) (JJ alternative) (NN possibility))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD found)
        (SBAR (IN that)
          (S
            (NP
              (NP
                (ADJP (FW in) (FW vitro))
                (NN splenocyte) (NN stimulation))
              (PP (IN with)
                (NP (NN TF))))
            (VP (VBD was)
              (VP (VBN associated)
                (PP (IN with)
                  (NP
                    (NP (JJ selective) (NN release))
                    (PP (IN of)
                      (NP (DT the) (NN monocyte) (NN chemoattractant) (NN molecule) (CD MIP-1α)))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN observation))
      (VP (MD may)
        (VP (VB explain)
          (NP
            (NP (DT the) (NN dominance))
            (PP (IN of)
              (NP (JJ mononuclear) (NNS cells)))
            (PP (IN in)
              (NP
                (NP (DT the) (JJ synovial) (JJ inflammatory) (NNS infiltrates))
                (PP (IN of)
                  (NP
                    (NP (DT the) (NNS joints))
                    (VP (VBN injected)
                      (PP (IN with)
                        (NP (NN TF))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Altogether))
      (NP (PRP$ our) (NNS observations))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP (NN TF))
            (VP (MD may)
              (VP (VB play)
                (NP (DT an) (JJ active) (NN role))
                (PP (IN during)
                  (NP (NN arthritis)))
                (PP (IN by)
                  (NP
                    (NP
                      (ADJP
                        (ADJP (JJ direct))
                        (CC and/or)
                        (ADJP (JJ indirect)))
                      (NN stimulation))
                    (PP (IN of)
                      (NP
                        (NP (NN influx))
                        (PP (IN of)
                          (NP (NNS monocytes)))
                        (PP (IN into)
                          (NP (DT the) (JJ synovial) (NN tissue)))))))))))))
    (. .)))

(
  (S
    (NP (NNS Abbreviations))))

(
  (S
    (S
      (S
        (NP (NN FCS))
        (VP (VBG =)
          (NP
            (NP (JJ fetal) (NN calf) (NN serum))
            (: ;)
            (NP (NN FVII) (JJ =) (NN factor) (NN VII))
            (: ;)
            (NP (NN IL) (JJ =) (NN interleukin) (: ;) (NN LPS) (JJ =) (NN lipopolysaccharide))
            (: ;)
            (NP (NN MIP) (JJ =) (NN macrophage) (JJ inhibitory) (NN protein)))))
      (: ;)
      (S
        (NP (NN RA))
        (VP (VBG =)
          (NP (JJ rheumatoid) (NN arthritis))))
      (: ;)
      (S
        (NP (NN RANTES))
        (VP (VBG =)
          (VP (VBN regulated)
            (PP (IN on)
              (NP
                (NP (NN activation) (JJ normal) (NN T-cell))
                (VP
                  (VP (VBN expressed))
                  (CC and)
                  (VP (VBN secreted))))))))
      (: ;)
      (NP (NN RTF) (JJ =) (JJ recombinant) (NN TF))
      (: ;)
      (NP
        (NP (NN SCID))
        (ADJP (JJ =) (JJ severe) (JJ combined) (JJ immunodeficient)))
      (: ;)
      (NP (NN TF) (JJ =) (NN tissue) (NN factor)))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (NP
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP (NNS Measurements))
        (PP (IN of)
          (NP (NN arthritis)))
        (PP (IN in)
          (NP (JJ murine) (NN knee) (NNS joints))))
      (. .))))

(
  (S
    (S
      (NP
        (NP
          (NP
            (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
            (NN Arthritis) (NN index))
          (CC and)
          (NP
            (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
            (NP (NN incidence))
            (PP (IN of)
              (NP (NN arthritis)))
            (PP (IN after)
              (NP
                (NP (JJ intra-articular) (NN injection))
                (PP (IN of)
                  (NP (NN TF)))))))
        (PRN (-LRB- -LRB-)
          (NP (CD 20) (NN μg/joint))
          (-RRB- -RRB-)))
      (ADVP (RB as))
      (VP (VBN evaluated)
        (PP (IN by)
          (NP (JJ histological) (NN examination)))))
    (. .)))

(
  (S
    (S
      (NP (NN Arthritis) (NN index))
      (VP (VBD was)
        (VP (VBN assessed)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (PP (IN in)
                  (NP (DT the)
                    (NP
                      (NP (NNS Materials))
                      (CC and)
                      (NP (NNS methods)))
                    (NN section)))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Asterisks))
      (VP (VBP indicate)
        (NP
          (NP (JJ significant) (NNS differences))
          (PP (IN of)
            (NP (DT the) (NNS means)))
          (PP (IN between)
            (NP
              (NP
                (NP (DT the) (NNS mice))
                (VP (VBG receiving)
                  (NP (NN TF))))
              (CC and)
              (NP (DT the) (NNS controls)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Figure) (CD 2))
        (: :)
        (NP
          (NP (JJ Morphological) (NNS changes))
          (PP (IN in)
            (NP (DT the) (NN joint)))
          (PP (IN after)
            (NP
              (NP (NN injection))
              (PP (IN of)
                (NP (NN TF))))))
        (. .))
      (NP
        (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
        (NN Histopathology)
        (PP (IN of)
          (NP
            (NP
              (NP (DT an) (JJ arthritic) (NN knee) (NN joint))
              (NP
                (NP (CD four) (NNS days))
                (PP (IN after)
                  (NP
                    (NP (NN injection))
                    (PP (IN of)
                      (NP (NN TF)))))))
            (PRN (-LRB- -LRB-)
              (NP (CD 20) (NN μg/joint))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Infiltration))
        (PP (IN of)
          (NP (JJ mononuclear) (NNS cells)))
        (PP (IN in)
          (NP (JJ synovial) (NN tissue))))
      (VP (VBZ is)
        (ADJP (JJ apparent))))
    (. .)))

(
  (S
    (NP
      (NP (JJ Original) (NN magnification) (NN ×20))
      (. .))))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
      (NP
        (NP (JJ Immunohistochemical) (NN staining))
        (PP (IN of)
          (NP (DT an) (JJ arthritic) (NN knee) (NN joint))))
      (, ,)
      (VP (VBG showing)
        (NP
          (NP (NNS cells))
          (VP (VBG expressing)
            (NP (NN Mac-1))))))
    (. .)))

(
  (S
    (NP
      (NP (JJ Original) (NN magnification) (NN ×40))
      (. .))))

(
  (S
    (S
      (NP
        (NP
          (NP (NN JC))
          (, ,)
          (NP (NN joint) (NN cavity))
          (: ;)
          (NP (NN C)))
        (, ,)
        (NP
          (NP (NN cartilage))
          (: ;)
          (NP (NN SH))
          (, ,)
          (NP (JJ synovial) (NN hyperplasy))
          (: ;)
          (NP (NN P))
          (, ,)
          (NP (NN pannus))
          (: ;)
          (NP (NN Er))
          (, ,)
          (NP (NN bone) (NN erosion))
          (: ;)
          (NP
            (ADJP (JJ ST))))
        (, ,))
      (NP (JJ synovial) (NN tissue)))
    (. .)))

(
  (S
    (S
      (NP (NNS Arrows))
      (VP (VBP indicate)
        (NP
          (NP (JJ inflammatory) (NNS cells))
          (PP (IN in)
            (NP
              (NP (NN synovia))
              (, ,)
              (NP (NN pannus) (NN formation))
              (CC and)
              (NP (NN cartilage) (NN destruction)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Figure) (CD 3))
        (: :)
        (NP
          (NP (NNS Lymphocytes))
          (CC and)
          (NP (NNS monocytes))))
      (VP (VBP are)
        (ADJP (JJ mandatory)
          (PP (IN for)
            (NP
              (NP (DT the) (NN development))
              (PP (IN of)
                (NP (JJ TF-induced) (NN arthritis))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Incidence))
        (PP (IN of)
          (NP (NN arthritis))))
      (VP (VBD was)
        (VP (VBN assessed)
          (PP (IN in)
            (NP
              (NP (NNS mice))
              (VP (VBN depleted)
                (PP (IN of)
                  (NP (JJ various) (JJ immune) (NNS cells)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Significant) (NNS differences))
        (PP (IN of)
          (NP
            (NP (NN incidence))
            (PP (IN of)
              (NP (NN arthritis)))))
        (PP (IN between)
          (NP (DT the) (NNS groups))))
      (VP (VBP are)
        (VP (VBN indicated))))
    (. .)))

